Skip to main content

Table 1 Clinical-pathological characteristics

From: Protective role of intravesical BCG in COVID-19 severity

Characteristics

Covid-19 patients (n = 43)

All BCG patients (n = 175)

BCG dosage, mg ± SD

39.64 ± 22.9

44.3 ± 25.5

BCG instillations, n ± SD

12.20 ± 8.1

13.25 ± 7.4

Induction completed, % (n)

86.0% (37)

95.4% (167)

Maintenance completed, % (n)

62.8% (27)

65.1% (114)

Maintenance therapy time, years ± SD

1.48 ± 0.83

1.11 ± 0.98

T stage

 Cis, % (n)

9.3% (4)

6.3% (11)

 Ta, % (n)

55.8% (24)

48.0% (84)

 T1, % (n)

34.9% (15)

38.9% (68)

Previous relapse, % (n)

55.8% (24)

42.9% (75)

BCG infection (“BCGitis”), % (n)

25.6% (11)

18.9% (33)